Efficacy of Clevidipine in Controlling Perioperative Hypertension in Neurosurgical Patients
Authors:
- Alex BekkerABAlex Bekker
- Sorosch DidehvarSDSorosch Didehvar
- Sunmi KimSKSunmi Kim
- John G. GolfinosJGJohn G. Golfinos
- Erik ParkerEPErik Parker
- Andrew SapsonASAndrew Sapson
- Michael HaileMHMichael Haile
- Richard KlineRKRichard Kline
- Mitchell LeeMLMitchell Lee
- 1 October 2010
- journal article
- Published by Wolters Kluwer Health in Journal of Neurosurgical Anesthesiology
- Vol. 22 (4) , 330-335
Abstract
Acute blood pressure (BP) elevations in neurosurgical patients are associated with serious neurologic, cardiovascular, or surgical site complications. Clevidipine, an ultra-short-acting dihydropyridine calcium antagonist, has been shown to be efficacious and safe for acute hypertension in cardiac surgery. This study assessed the efficacy and safety of clevidipine in controlling perioperative hypertension in the neurosurgical setting. Patients scheduled for intracranial surgery were prospectively enrolled after giving consent. Clevidipine (0.5 mg/mL in 20% lipid solution, which was to be initiated at 10 mg/h and titrated to effect) was administered as the primary antihypertensive agent for perioperative hypertension, with target BPs of less than 130 mm Hg. Other vasoactive drugs were administered as needed for treating systolic BP (SBP) less than 90 mm Hg or greater than 130 mm Hg. The primary study endpoint was the proportion of patients not requiring rescue antihypertensives to maintain target SBP (<130 mm Hg). Twenty-two patients were enrolled. One patient did not require antihypertensive therapy. Seventeen patients (17 of 21, 81%) were treated with clevidipine alone; one received clevidipine in the postanesthesia care unit only. Twenty-eight hypertensive episodes (defined as any new acute BP elevation requiring clevidipine initiation) were documented. SBP was reduced to target level within 15 minutes in 22 of 28 episodes (78.6%). Two mild hypotensive episodes occurred after the initiation of clevidipine infusion; these transient decreases in BP were treated with vasoactive drugs and resolved within 5 minutes. Clevidipine is effective and safe for perioperative hypertension in patients undergoing intracranial procedures. Rapid control of BP is possible with higher starting doses. Drug effects resolved rapidly after drug discontinuation.Keywords
This publication has 22 references indexed in Scilit:
- The ECLIPSE Trials: Comparative Studies of Clevidipine to Nitroglycerin, Sodium Nitroprusside, and Nicardipine for Acute Hypertension Treatment in Cardiac Surgery PatientsAnesthesia & Analgesia, 2008
- The Effect of Dexmedetomidine on Perioperative Hemodynamics in Patients Undergoing CraniotomyAnesthesia & Analgesia, 2008
- Pharmacodynamic, Pharmacokinetic and Clinical Effects of Clevidipine, an Ultrashort‐Acting Calcium Antagonist for Rapid Blood Pressure ControlCardiovascular Drug Reviews, 2004
- Cerebral Hyperemia During Recovery from General Anesthesia in Neurosurgical PatientsAnesthesia & Analgesia, 2002
- Recovery from Anesthesia and Postoperative Extubation of Neurosurgical PatientsJournal of Neurosurgical Anesthesiology, 1999
- PATIENT COMFORTAnesthesia & Analgesia, 1990
- Treatment of intraoperative hypertensive emergencies in patients with intracranial diseaseThe American Journal of Cardiology, 1989
- Intracranial pressure monitoring after elective intracranial surgeryJournal of Neurosurgery, 1988
- Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertensionThe American Journal of Cardiology, 1987
- Cerebral edema associated with craniectomy and arterial hypertension.Stroke, 1985